Based on the key measurements obtained from Eli Lilly's financial statements, Eli Lilly and may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Eli Lilly's Total Liabilities is fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.5 B in 2025, whereas Total Stockholder Equity is likely to drop slightly above 9.2 B in 2025. Key indicators impacting Eli Lilly's financial strength include:
The financial analysis of Eli Lilly is a critical element in measuring its lifeblood. Investors should not minimize Eli Lilly's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Check Eli Lilly's Beneish M Score to see the likelihood of Eli Lilly's management manipulating its earnings.
Eli Lilly Stock Summary
Eli Lilly competes with Johnson Johnson, Bristol Myers, AbbVie, Pfizer, and Merck. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Eli Lilly. It measures of how well Eli is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Eli Lilly brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Eli had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Eli Lilly has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Eli Lilly's current stock value. Our valuation model uses many indicators to compare Eli Lilly value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eli Lilly competition to find correlations between indicators driving Eli Lilly's intrinsic value. More Info.
Eli Lilly and is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.18 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eli Lilly and is roughly 5.50 . At this time, Eli Lilly's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eli Lilly's earnings, one of the primary drivers of an investment's value.
Eli Lilly's Earnings Breakdown by Geography
Eli Lilly Systematic Risk
Eli Lilly's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eli Lilly volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Eli Lilly correlated with the market. If Beta is less than 0 Eli Lilly generally moves in the opposite direction as compared to the market. If Eli Lilly Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eli Lilly is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eli Lilly is generally in the same direction as the market. If Beta > 1 Eli Lilly moves generally in the same direction as, but more than the movement of the benchmark.
Eli Lilly Thematic Clasifications
Eli Lilly and is part of several thematic ideas from Compulsion to ESG Investing. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Eli Lilly Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eli Lilly's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Eli Lilly growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Eli Lilly help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eli Lilly and. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eli Lilly and based on widely used predictive technical indicators. In general, we focus on analyzing Eli Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eli Lilly's daily price indicators and compare them against related drivers.
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.